Live bio therapeutics

#Drug candidates #Live bio therapeutics #Pharmaceutical

4D pharma merger with Longevity to gain NASDAQ listing

4D pharma, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome – and Longevity Acquisition a NASDAQ-listed Special Purpose Acquisition Company (SPAC), have announced a proposed merger. The deal is worth up to $37.6 million to 4D pharma. Read More

#News